ResMed Inc. (RMD)’s Sleep Apnea Leadership Supports Growth Despite Rising Competitive Pressures
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market.
Resmed Inc (RMD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 1,129,739 | $220,163,536 | +151% | 0.1% |
| 2. | AQR Capital Management Cliff Asness | 910,623 | $177,143,337 | +161% | 0.06% |
| 3. | Citadel Investment Group Ken Griffin | 508,284 | $99,054,386 | +54% | 0.01% |
| 4. | Giverny Capital Francois Rochon | 387,665 | $75,548,155 | +69% | 2.54% |
| 5. | Ilex Capital Partners Jonas Diedrich And David Sutton | 355,754 | $69,329,340 | -15% | 1.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.13 | 2,487 | $171,926.31 | 19,216 | 2016-08-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $226.33 | 4,991 | $1,129,637.49 | 479,803 | 2026-10-07 | Filing | |
| $222.44 | 4,991 | $1,110,190.55 | 466,256 | 2026-09-08 | Filing | |
| $234.73 | 970 | $227,688.10 | 51,803 | 2026-09-02 | Filing | |
| $205.69 | 4,991 | $1,026,596.29 | 466,256 | 2026-08-07 | Filing | |
| $225.00 | 8,000 | $1,800,000.00 | 52,773 | 2026-08-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 84,518 | $18,686,864 | 0.31% | |
| 2. | 63,623 | $14,067,045 | 0.37% | |
| 3. | 43,686 | $9,905,019 | 0.23% | |
| 4. | 42,604 | $9,419,744 | 0.25% | |
| 5. | 41,447 | $9,163,932 | 0.05% |
News See All
ResMed's (RMD) Sleep Business Booms Even As One Product Stumbles
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth.
The Week That Was, The Week Ahead: Macro and Markets, August 16
U.S. stocks ended another positive week near record highs, although Friday’s weak retail sales report took some of the shine off the rally. The S&P...
Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. ResMed Inc. (NYSE:RMD) is among the best healthcare stocks.
10 Best Healthcare Stocks to Buy According to Wall Street Analysts
In this article, we will be taking a look at the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. The U.S.
Is ResMed Inc. (RMD) A Good Stock To Buy Now?
Is RMD a good stock to buy? We came across a bullish thesis on ResMed Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on RMD.
10 Most Undervalued Large Cap Stocks to Buy According to Analysts
In this article, we will discuss the 10 Most Undervalued Large Cap Stocks to Buy According to Analysts.
ResMed Inc. (NYSE:RMD) Q3 2026 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q3 2026 Earnings Call Transcript April 30, 2026 Operator: Welcome to the Q3 Fiscal Year 2026 ResMed Inc. Earnings Conference Call.
8 Best Long-Term ASX Stocks to Buy Right Now
In this piece, we shed light on the 8 Best Long-Term ASX Stocks to Buy Right Now.
ResMed Inc. (RMD) Gains Analyst Confidence as Price Targets Rise on Strong Earnings
ResMed Inc. (NYSE:RMD) is one of the best medical technology stocks to invest in. On January 30, KeyBanc Capital Markets lifted its price target on ResMed Inc.
Hedge Fund Resource Center